Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of GSK's DTPa/Hib Vaccine in Chinese Infants
NCT00379977Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccine in diphtheria, Tetanus, pertussis and 1 more, sponsored by GSK. Primary endpoints: Occurrence of solicited symptoms at 4 days, Occurrence of unsolicited symptoms at 31 days and 1 more. Started Sep 2006; status: completed.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccine
03
Conditions
diphtheriaTetanuspertussisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00379977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379977.